Rosiglitazone and implications for pharmacovigilance
- PMID: 17569897
- PMCID: PMC1892466
- DOI: 10.1136/bmj.39245.502546.BE
Rosiglitazone and implications for pharmacovigilance
Abstract
Postsurveillance data should be systematically collected, timely, and publicly available
Conflict of interest statement
References
-
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med Published online 21 May 2007 - PubMed
-
- National Institute for Health and Clinical Excellence. NICE implementation uptake report: glitazones (rosiglitazone and pioglitazone). 2007. www.nice.org.uk/page.aspx?o=423524
-
- Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones N, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med Published online 5 June 2007 - PubMed
-
- Psaty BM, Furberg CD. The record of rosiglitazone and the risk of myocardial infarction. N Engl J Med Published online 5 June 2007 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical